Sandoz exec joins Alvotech as CEO

Notching up another defection from Novartis’ generics/biosimilars subsidiary, Icelandic biopharmaceutical company Alvotech today announced the appointment of Mark Levick as chief executive, effective August 5, 2019.

Mr Levick brings over 18 years of global industry experience, with a very impressive track record of value creation and success in bringing new biosimilars to market. Prior to joining Alvotech, he was the head of development of Sandoz biopharmaceuticals. He succeeds Rasmus Rojkjaer, who has stepped down from his role.+

During his time at Sandoz, Mr Levick oversaw the successful approval of five biosimilar medicines in major markets (etanercept, rituximab, adalimumab, infliximab and peg-filgrastim), taking Sandoz to the industry-leading position with a total of eight approved biosimilar products. Previously, Mr Levick held roles of increasing responsibility at Novartis in the USA and Switzerland, including the global head of biologics, clinical development and respiratory development, and he played a pivotal role in the approval of innovative biopharmaceutical medicines.